13F Holdings
中文EN

IRMD IRADIMED CORP

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1325618 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.0%
TTM net income YoY13.2%
TTM EPS YoY13.3%
Revenue 3-yr CAGR12.4%
Net income 3-yr CAGR13.7%

Margins

Gross margin75.5%
Operating margin32.3%
Net margin26.8%
FCF margin29.3%
EBITDA margin33.9%

Returns

ROE23.4%
ROA20.3%
ROIC (approx.)52.3%
Asset turnover0.76x

Leverage & solvency

Liabilities / assets12.1%
Debt / equity0.00x
Current ratio8.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.13x
Accruals ratio-2.7%
Payout ratio67.7%
Capex / revenue1.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$83.81M$73.24M$65.56M$53.30M$41.81M
Cost of revenue$19.49M$16.89M$15.40M$12.02M$9.76M
Gross profit$64.32M$56.35M$50.16M$41.28M$32.05M
R&D expense$2.98M$2.83M$2.86M$2.28M$1.91M
SG&A expense$17.78M$15.94M$15.12M$10.70M$9.77M
Operating income$26.15M$21.96M$20.04M$15.63M$9.82M
Pretax income$28.36M$24.27M$21.74M$16.18M$9.84M
Income tax$5.88M$5.04M$4.55M$3.35M$510,816
Net income$22.48M$19.23M$17.19M$12.83M$9.33M
EBITDA$27.31M$22.78M$20.80M$16.30M$11.22M
EPS (basic)1.771.521.361.020.76
EPS (diluted)1.751.501.351.020.74
Weighted avg. shares (diluted)12.85M12.78M12.72M12.64M12.59M
Balance sheet
Cash & equivalents$51.16M$52.23M$49.76M$57.96M$62.00M
Receivables$13.67M$10.56M$12.22M$13.27M$5.14M
Inventory$11.62M$10.40M$12.82M$5.37M$4.30M
Current assets$81.20M$75.24M$76.00M$77.49M$76.24M
PP&E, net$23.86M$16.81M$9.29M$2.40M$2.07M
Intangibles$3.38M$3.10M$2.52M$2.07M$1.12M
Total assets$108.78M$98.33M$92.16M$85.51M$82.88M
Current liabilities$10.18M$8.51M$16.33M$8.55M$6.82M
Total liabilities$14.16M$11.51M$20.74M$11.84M$10.71M
Shareholders' equity$94.62M$86.82M$71.42M$73.67M$72.17M
Shares outstanding12.78M12.71M12.66M12.59M12.54M
Cash flow statement
Operating cash flow$24.95M$25.62M$13.47M$10.04M$11.26M
Capital expenditure$7.76M$8.01M$7.44M$823,019$482,325
Free cash flow$17.18M$17.62M$6.02M$9.22M$10.78M
Investing cash flow-$8.42M-$8.82M-$8.01M-$1.37M$648,241
Financing cash flow-$17.60M-$14.34M-$13.66M-$12.71M$24,425
Depreciation & amortization$1.17M$818,000$765,180$670,673$1.41M
Stock-based compensation$2.92M$2.52M$2.19M$1.39M$1.46M
Dividends paid$15.04M$13.68M$13.22M$12.56M—

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.